GOOD NEWS丨YEEDOZENCOM and Guangzhou Green Cross reached a strategic cooperation
On November 10, 2023, Beijing YEEDOZENCOM Tech.Ltd. with its team went to Guangzhou to convene a project meeting on the background of strategic cooperation with Green Cross Pharmaceutical Co., Ltd. The meeting involved Liang Feng, President of Green Cross, Hu Gongyun, Vice President of Green Cross R&D; Li Hongxia, Vice President of Green Cross Marketing; Wei Xinghua, Director of Green Cross Marketing; Gong Zihua, Regulatory Affairs Manager of Green Cross; Shao Ling, Clinical Project Manager of Green Cross; Huang Xiaopei, Assistant of Vice President of Green Cross; Dong Lingyun, General Manager of YEEDOZENCOM; Huang Haiyan, Deputy General Manager and Head of Business Development Department and Medical Affairs Department; Zhang Xiaohong, Deputy General Manager and Head of Clinical Operation Department; Qin Ningbo, Business Development director participated in the meeting jointly and reached a consensus on cooperation and signed a strategic cooperation agreement, which laid a good foundation for future project communication and promotion.
At the meeting, Feng Liang, President of Green Cross Group, first reviewed the successful cooperation experience between the two parties, and gave a high degree of recognition to the team strength and professional skill of YEEDOZENCOM, indicating that the service of YEEDOZENCOM in the professional field has largely made up for a certain gap of Green Cross.
Lingyun Dong, General Manager of YEEDOZENCOM responded that Green Cross has given great trust to YEEDOZENCOM in the early days of its establishment. Through two successful clinical research projects, it has laid a solid foundation for the cooperation between the two parties. At the same time, in the process of YEEDOZENCOM's continuous growth, we hope to keep up with the development of Green Cross and provide it with more professional and accurate services.
In the positive response of both parties, the strategic cooperation agreement was signed by Vice President of Green Cross Mr.Hu, and the Deputy General Manager of YEEDOZENCOM Mrs.Huang, representing the formal conclusion of the strategic cooperation between the two parties.
Adhering to the vision of being a "CRO service provider with both an in-depth and compassionate attitude", YEEDOZENCOM provides full life cycle services for more than 350 pharmaceutical companies at home and abroad. As of November 2023, more than 30 customers have reached strategic cooperation with YEEDOZENCOM, and nearly 100 cooperation projects have been completed under the strategic agreement, it is highly praised by the pharmaceuticals fields for its professional team and high level of service.
About YEEDOZENCOM
Since its establishment 13 years ago, YEEDOZENCOM has provided 650+ drug regulatory affairs, clinical trials, and other related services for 350+ domestic and foreign pharmaceutical enterprises, covering phase I-IV clinical trials and mass balance /DDI/ pharmacokinetics in special populations and other clinical pharmacological study, and assisted more than 10 innovative drugs and more than 100 generic drugs successfully listed.
About Green Cross
Guangzhou Green Cross Pharmaceutical which was founded in 1991, is a comprehensive pharmaceutical enterprise, mainly engaged in R&D, production, and sales of high-end parenteral nutrition preparations and a variety of chemicals. The company gathers the whole closed-loop industrial chain with its own complete production, R&D, and sales system, and has a wholly-owned R&D subsidiary Saifeng Pharmaceutical, a holding subsidiary related to production Huineng Pharmaceutical, and a wholly-owned subsidiary related to sales Kemao Pharmaceutical. The company won the certification of "High-tech Enterprise in Guangdong Province" from 2018 to 2021. In 2021, it has planned a new land of nearly 300 acres to establish Shandong HAORUIEN and Guangdong HAORUIEN which are two major production bases located in Shandong and Qingyuan. Since its establishment, Green Cross has been adhering to the mission of medical service providers—— R&D comes first, with people-oriented pharmaceutical principles, and striving to become one of the most well-respected pharmaceutical companies.
